Harwin Peter Evan 的 Form 4 申報
Oruka Therapeutics, Inc.（ORKA），2026/7/1 申報
- 申報編號
- 0001104659-26-080009
- 申報時間
- 2026/7/1 21:30 ET
- 交易日
- 2026/7/1
- 申報延遲
- 當天
- 10b5-1 計畫
- 沒有勾選
這份申報列了 2 筆非衍生性交易、1 筆衍生性交易。公開市場賣出合計 $3.00 億。交易當天就申報。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Harwin Peter EvanCIK 0001663607 | 董事、持股 10% 以上大股東 |
| Fairmount Healthcare Fund II L.P.CIK 0001769651 | 董事、持股 10% 以上大股東 |
| Fairmount Funds Management LLCCIK 0001802528 | 董事、持股 10% 以上大股東 |
| Kiselak TomasCIK 0001830177 | 董事、持股 10% 以上大股東 |
| Fairmount Healthcare Co-Invest III L.P.CIK 0002009690 | 董事、持股 10% 以上大股東 |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2026/7/1 | Common Stock | C轉換取得 | +3,553,410 | –F1 | – | 4,685,364 | 間接 | |
| 2026/7/1 | Common Stock | S賣出處分 | −3,553,410 | $84.43 | −$300,014,406.3 | 1,131,954 | 間接 |
衍生性證券（表 II）
選擇權、認股權證、限制型股票單位等。股數是標的股票的股數；單價與金額是衍生證券本身的價格，交易後持有是衍生證券的單位數。
| 交易日 | 證券 | 交易 | 標的股數 | 單價 | 金額 | 交易後持有 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2026/7/1 | Common Stock | C轉換處分 | −3,553,410 | $0.00 | $0 | 94,497 | 間接 |
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
Each share of Series B Preferred Stock is convertible at the option of the holder into 83.3332 shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. On July 1, 2026, the Reporting Persons converted 42,641 shares of Series B Preferred Stock into 3,553,410 shares of Common Stock for no cash consideration, in accordance with the Certificate of Designation for the Series B Convertible Preferred Stock.
表 I 有 1 筆交易的價格引用這則附註。
備註
Fairmount may be deemed a director by deputization of Issuer by virtue of the fact that Peter Harwin serves on the board of directors of the Issuer and is also a Managing Member of Fairmount.